A Pilot Study To Assess Mosquito Transmissibility of Plasmodium vivax In Participants Inoculated intravenously with the parasite Isolate Hmpbs-Pv

QIMR Berghofer Medical Research Institute0 个研究点目标入组 6 人开始时间: 2013年9月11日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•1.Adults (males and non pregnant and non lactating females), aged between 18 and 50 years who do not live alone (from Day 0 until at least the end of the antimalarial drug treatment).
•2.BMI within the range 18–30 kg/m2; weight greater than 50kg, with good peripheral venous access
•3.Able and willing (in the Investigator’s opinion) to comply with all study requirements.
•4.Non-smokers.
•5.Female participants of childbearing potential must have adequate contraception in place.
•6.Blood group A Duffy antigen positive.

•1.History of clinical malaria, or traveled to or lived (greater than 2 weeks) in a malaria-endemic country during the past 12 months.
•2.Known severe reaction to mosquito bites other than local itching and redness.
•3.Evidence of increased cardiovascular disease risk.
•4.History of a severe allergic reaction, anaphylaxis or convulsions following any vaccination or infusion.
•5.Being unwilling to defer blood donations for the duration of the trial and for at least 6 months after the end of their involvement in the study.
•6.A history of clinically significant ECG abnormalities and known pre-existing prolongation of the QTc interval considered clinically significant.
•7. Have ever received a blood transfusion.

发起方